CELLINK
Develops innovative 3D bioprinting systems including state-of-the-art bioprinters and bioinks used for printing human tissues and organs.
- CEO / Founder
- Erik Gatenholm
- Team Size
- Approximately 1,000 employees
- Stage
- Public
- Total Funding
- $315M
- Latest Round
- IPO
- Key Investors
- Erik Penser Bank AB, Other institutional and strategic investors
Technology & Products
Key Products
["BIO X series bioprinters (including BIO X and BIO X6)","Holograph X 3D bioprinter","CELLINK bioinks and consumables"]
Technological Advantage
Scalable automation solutions and integrated workflows that lower cost barriers and streamline bioprinting processes.
Differentiation
Value Proposition
Enables creation of complex, biomimetic tissues for drug discovery, personalized medicine, regenerative therapies, and cosmetic testing at lower costs with scalable, user-friendly technologies.
How They Differentiate
Combines scalable, cost-effective bioprinting hardware with an extensive portfolio of bioinks and a strong focus on automation and integrated workflows.
Market & Competition
Target Customers
Researchers, pharmaceutical companies, healthcare providers, and academic institutions
Industry Verticals
["Biotechnology","Pharmaceuticals","Healthcare","Regenerative Medicine","Cosmetic Research"]
Competitors
Organovo Holdings; Allevi; Materialise
Growth & Milestones
Growth Metrics
Achieved rapid market valuation at IPO and significant revenue growth through strategic acquisitions and global expansion
Major Milestones
["Released the world’s first universal bioink","IPO in 2017","Acquisition of Dispendix GmbH in 2018","Strategic acquisitions including Advanced BioMatrix","Key partnerships with industry leaders such as MedImmune"]
Notable Customers
Harvard University; Merck; Leading pharmaceutical companies; Academic institutions